MS-20 is under clinical development by Microbio and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MS-20’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MS-20 overview

MS-20 is under development for the treatment of non-small cell lung cancer and ulcerative colitis of IBD. It was under development of hepatocellular carcinoma, neutropenic fever in cancer patients undergoing chemotherapy and cachexia in liver cancer patients. The drug candidate is derived from the fermentation of organic, non-GM soybeans. It is developed using the proprietary fermentation platform. MS-20 has proven effect in enhancing intestinal beneficial bacteria. MS-20 is protected by a family of strategic international patents. It is administered through oral route.

Microbio overview

Microbio is a drug development company that discovers, develops, manufactures and commercializes drugs in the areas of cancer, autoimmune and other metabolic diseases. The company offers botanical drugs, monoclonal antibodies, new chemical entities and glyco-molecules, among others. It provides products such as leeherb, cotton field, oneness herb, microsoy, and others. Microbio undertakes clinical trails for several drugs. The company’s products find application in the treatment of diseases such as fatigue and appetite loss, anemia, colorectal cancer, liver cancer, rheumatoid arthritis and hepatitis C, among others. Microbio is headquartered in Taipei, Taiwan.

For a complete picture of MS-20’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.